- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Patent holdings for IPC class A61K 31/513
Total number of patents in this class: 4155
10-year publication summary
|
304
|
337
|
317
|
293
|
382
|
319
|
347
|
334
|
297
|
236
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Abbvie Inc. | 1836 |
81 |
| Merck Sharp & Dohme LLC | 3734 |
63 |
| Gilead Sciences, Inc. | 2222 |
61 |
| Taisho Pharmaceutical Co., Ltd. | 852 |
56 |
| Corcept Therapeutics, Inc. | 370 |
54 |
| Immunomedics, Inc. | 239 |
44 |
| Takeda Pharmaceutical Company Limited | 2712 |
36 |
| Bristol-myers Squibb Company | 4742 |
35 |
| Boehringer Ingelheim International GmbH | 4493 |
32 |
| The Regents of the University of California | 20745 |
30 |
| F. Hoffmann-La Roche AG | 7837 |
29 |
| Genentech, Inc. | 4104 |
29 |
| MyoKardia, Inc. | 113 |
26 |
| Novartis AG | 10262 |
25 |
| Pfizer Inc. | 3386 |
24 |
| Cipla Limited | 478 |
24 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3229 |
24 |
| Amgen Inc. | 4427 |
23 |
| Sanofi | 4301 |
22 |
| Ipsen Biopharm Limited | 366 |
21 |
| Other owners | 3416 |